Beijing’s First CAR-T Cell Therapy Approved for Lymphoma

Beijing's first locally approved CAR-T product signals that China's advanced cell-therapy manufacturing base is broadening beyond its established clusters, with the capital now hosting an approved commercial asset. The significance lies less in the indication itself, which targets a well-defined relapsed or refractory lymphoma population, than in what it implies for domestic self-sufficiency in a complex, high-cost modality. Access and reimbursement will be the pressure points, as they are for CAR-T globally. Whether additional Beijing-developed cell therapies follow, and how pricing and hospital capacity absorb them, is the open question worth tracking.